Today marks the 7th anniversary of the incorporation of GPN Vaccines. We would like to extend our deepest thanks to our investors, employees, advisors, consultants, partners, service providers and students who have made it possible for us to build a thriving Australian biotech company.
GPN Vaccines
Biotechnology Research
Yarralumla, Australian Capital Territory 1,382 followers
Developing innovative vaccines against the world's most important bacterial pathogens.
About us
GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens.
- Website
-
http://www.gpnvaccines.com
External link for GPN Vaccines
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Yarralumla, Australian Capital Territory
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
14/65 Musgrave St
Yarralumla, Australian Capital Territory 2600, AU
Employees at GPN Vaccines
-
Tim Hirst
-
Barry Palte
Health of People and Planet, Chairman EQ Capital Partners, Emeritus Chairman International Association of Investment Bankers
-
Paul Rolan
Consultant in development of medicines
-
Nerissa Lakhan
Clinical Project Manager at GPN Vaccines, PhD in Medicine, Board Certified MSL
Updates
-
“Great things in business are never done by one person, they are done by a team of people” - Steve Jobs. Our team is at the centre of all we do and we invest in them regularly. Yesterday we gathered for a full day of team building. We listened, reflected, learned and laughed together and all came away feeling even more committed to our goals. A big thank you to Wayne Enright from Operation Flinders Foundation for facilitating such a fun and enlightening day, and Adelaide Skydeck for the views! Tim Hirst James Selkirk FCA Paul Rolan Lauren Giorgio Mohammed Alsharifi Miriam Dodd Antiksha Joshi Brooke Dilmetz Carla Gallasch Chloe Gates Elizabeth Tran Erin Brazel Eve Kennedy Malachi Obst Ricky Williams Shuai L. Janice Henrichs Nerissa Lakhan Rachel Chin Mariana Couto Moniz
-
... and we're off! First three doses given today in our second clinical study in older adults. https://lnkd.in/g-Ryngwv
-
Such a pleasure to host the wonderful Dr Alma Fulurija in Adelaide this week! A whirlwind two days of sharing ideas (and a few war stories), topped off with an inspiring seminar. Thanks so much for coming Alma!
-
Our new website is now live! Designed and built by EDynam - Adelaide Web Design Studio with photos by Headshots Adelaide, graphic design by Animate Your Science and videography by Trace Elements Media, we are pleased to say our website is 100% South Australian! Big thanks to Greg Lawrynowicz, Anna Scott, Juan Miguel Balbin, PhD and Tim Ash for helping us with this project.
Home
https://gpnvaccines.com
-
We are thrilled to be finalists in the South Australian Premier's Business and Export Awards! With humble origins back in 2017; we have now entered clinical trials, raised $35M in capital, built a team of 20 in Adelaide, developed four patent families and are on track to deliver on our mission of creating innovative vaccines against the world's most important bacterial pathogens. Winners will be announced on 11th October - stay tuned!
-
We are delighted to support Carla Gallasch as the University of Adelaide's first PhD student to be awarded a National Industry PhD Program Scholarship! Building on years of know how and learnings from the Gamma-PN program, Carla is working on a new vaccine to provide protection against Haemophilus influenzae - a major cause of ear infections in children.
Don’t miss out! Applications are closing soon for universities to apply under Round 4 of the National Industry PhD Program (NIPP). The program supports PhD candidates to undertake industry-focused research projects and develop the knowledge and skills to better translate university research into new products and services. The program is supporting University of Adelaide student Carla and industry partner, GPN Vaccines, to develop a vaccine for bacteria that can cause middle-ear and lung infections. GPN Vaccines CEO Professor Tim Hirst said ‘The NIPP was a seal of approval for the approach we are taking, which is to identify brilliant students and support them to do translational research.’ Applications close 9 August 2024. To find out how to participate in the program, visit http://srkr.io/6047M1W
-
GPN Vaccines is building its clinical team and is seeking an experienced Clinical Project Manager to work with our Chief Medical Officer. The role can be either full or part-time depending on experience and remote candidates are encouraged to apply. Industry experience is essential, and those with GCP training and a track record of running vaccine studies will be highly regarded.
-
Team lunches are getting bigger at GPN Vaccines! Celebrating the retirement of Professor James Paton and Leigh Willis who have both made invaluable contributions to the company, and welcoming new staff and students Chloe Gates, Ricky Williams, Brooke Dilmetz, Janice Henrichs and Mariana Couto Moniz.